Agilent Technologies (NYSE:A) PT Raised to $90.00 at Oppenheimer

Agilent Technologies (NYSE:A) had its price objective lifted by investment analysts at Oppenheimer from $67.00 to $90.00 in a report released on Tuesday, MarketBeat reports. The brokerage currently has an “outperform” rating on the medical research company’s stock. Oppenheimer’s price objective would suggest a potential downside of 38.95% from the company’s current price.

A number of other research firms also recently commented on A. Citigroup increased their price objective on shares of Agilent Technologies from $130.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Evercore ISI decreased their price objective on shares of Agilent Technologies from $135.00 to $132.00 and set an “in-line” rating for the company in a report on Wednesday, February 28th. Wolfe Research assumed coverage on shares of Agilent Technologies in a report on Wednesday, December 13th. They set an “outperform” rating and a $140.00 price objective for the company. TheStreet raised shares of Agilent Technologies from a “c+” rating to a “b-” rating in a report on Friday, December 8th. Finally, StockNews.com raised shares of Agilent Technologies from a “hold” rating to a “buy” rating in a report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, Agilent Technologies has an average rating of “Moderate Buy” and a consensus target price of $138.29.

Agilent Technologies Trading Up 2.1 %

Shares of Agilent Technologies stock opened at $147.41 on Tuesday. Agilent Technologies has a fifty-two week low of $96.80 and a fifty-two week high of $151.58. The firm has a market cap of $43.20 billion, a PE ratio of 35.10, a P/E/G ratio of 4.41 and a beta of 1.11. The business’s fifty day moving average is $137.60 and its two-hundred day moving average is $126.13. The company has a quick ratio of 2.04, a current ratio of 2.68 and a debt-to-equity ratio of 0.41.

Agilent Technologies (NYSE:A) last issued its quarterly earnings results on Tuesday, February 27th. The medical research company reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.22 by $0.07. Agilent Technologies had a return on equity of 27.09% and a net margin of 18.35%. The company had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the company posted $1.37 EPS. The business’s revenue for the quarter was down 5.5% compared to the same quarter last year. Analysts anticipate that Agilent Technologies will post 5.51 earnings per share for the current year.

Insider Transactions at Agilent Technologies

In related news, CEO Michael R. Mcmullen sold 52,297 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the transaction, the chief executive officer now directly owns 253,909 shares of the company’s stock, valued at $38,086,350. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Agilent Technologies news, Director Heidi Fields sold 1,658 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $144.34, for a total value of $239,315.72. Following the completion of the sale, the director now directly owns 54,976 shares in the company, valued at $7,935,235.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael R. Mcmullen sold 52,297 shares of Agilent Technologies stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $150.00, for a total transaction of $7,844,550.00. Following the completion of the sale, the chief executive officer now owns 253,909 shares of the company’s stock, valued at $38,086,350. The disclosure for this sale can be found here. Insiders have sold a total of 61,610 shares of company stock valued at $9,220,333 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Institutional Trading of Agilent Technologies

A number of institutional investors have recently added to or reduced their stakes in the business. Money Concepts Capital Corp acquired a new stake in shares of Agilent Technologies in the fourth quarter worth $26,000. Livelsberger Financial Advisory acquired a new stake in shares of Agilent Technologies in the fourth quarter worth $26,000. MV Capital Management Inc. lifted its stake in shares of Agilent Technologies by 120.7% in the fourth quarter. MV Capital Management Inc. now owns 192 shares of the medical research company’s stock worth $27,000 after buying an additional 105 shares during the last quarter. VisionPoint Advisory Group LLC acquired a new stake in shares of Agilent Technologies in the fourth quarter worth $29,000. Finally, Ancora Advisors LLC acquired a new stake in shares of Agilent Technologies in the fourth quarter worth $34,000. 87.42% of the stock is currently owned by institutional investors and hedge funds.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.